Cycle Pharmaceuticals
As of the edition of 20 October 2026, Cycle Pharmaceuticals runs 6 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Applied Therapeutics, Inc.: acquired in 2026
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Status not established | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nilotinib | Ends 2032 (patent) | 0 |
| Fingolimod | none listed | 9 |
| Nitisinone | none listed | 2 |
| Reserpine | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Nutrition and metabolism: 4 trials led
- Inherited and neonatal: 3 trials led
- Nervous system: 3 trials led